Pronto disponible para inscripción
This study will open for enrollment soon. Please contact the study team for more information and check back frequently.

Spyre_Skyline-UC_Jawitz - Clinical Trial

¿Cuál es el Propósito de este estudio?

If you can join, you will be placed in Part A or Part B based on when you start. In Part A, you will get one of three study medicines: SPY001, SPY002, or SPY003. In Part B, you will get one of these medicines, a mix of two medicines, or a placebo, which does nothing. The study will last about 97 weeks, and you will have around 20 visits or phone calls. During these, doctors will do tests like blood draws, endoscopy with biopsy, heart checks, and x-rays.

¿Cuál es la Condición que se está estudiando?

Moderately to Severely Active Ulcerative Colitis

¿Quién puede participar en el Estudio?

To join this study, you must be 18 years or older and have ulcerative colitis that is moderate to severe. If you take steroid pills, your dose must stay the same for at least 2 weeks before getting the study medicine. You can join if other treatments for ulcerative colitis did not work well for you, stopped working, or caused bad side effects.

Grupo etario
Adultos

¿Qué Implica?

This study wants to learn how three medicines, called SPY001, SPY002, and SPY003, affect people who have a sickness called ulcerative colitis. Ulcerative colitis is a disease that causes swelling and sores in the large intestine.

Detalles del Estudio

Título Completo
Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis
Investigador Principal
Nicole G. Jawitz, MD
Especialista en gastroenterología
Número de Protocolo
IRB: PRO00118888
NCT: NCT07012395
Fase
Phase II
ClinicalTrials.gov
Estado de inscripción
Pronto disponible para inscripción
Apoye la investigación de Duke Health o rinda homenaje a un ser querido con un regalo conmemorativo.
Contribuya a Duke Health